Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9425-9426
10.1182/blood-2022-170181